Medullary thyroid cancer – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 02 Jun 2026 12:27:17 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Medullary thyroid cancer – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A study of EP0031 and drug combination for patients with advanced cancers having changes in the RET gene https://clinicaltrials.eu/trial/a-study-of-ep0031-and-drug-combination-for-patients-with-advanced-cancers-having-changes-in-the-ret-gene/ Thu, 30 Apr 2026 13:08:43 +0000 https://clinicaltrials.eu/trial/a-study-of-ep0031-and-drug-combination-for-patients-with-advanced-cancers-having-changes-in-the-ret-gene/ This study is looking at people who have advanced cancers with changes in a gene called RET. When the RET gene is altered, it can cause different types of cancer to grow. The study will test a medicine called EP0031, which is given as a capsule by mouth. Some people in the study may also receive standard chemotherapy medicines including cisplatin, carboplatin, or pemetrexed, which are given through a vein. The main types of cancer being studied include lung cancer (specifically a type called non-small cell lung cancer or NSCLC with RET fusion) and a type of thyroid cancer called medullary thyroid cancer or MTC with RET mutation. The study also includes people with other types of cancer that have RET changes. Some people joining the study will have already received treatment with other RET-targeted medicines, while others will not have received these treatments before.

The purpose of the study is to find out if EP0031 is safe and how well it works in treating cancers with RET changes. The study is divided into different parts called modules. Module A will look at the safety of EP0031 and help determine the right dose to use. Modules B and C will test how well EP0031 works at shrinking tumors and will continue to monitor safety. The study will measure how tumors respond to treatment, how long the response lasts, and how long people live without their cancer getting worse. For some people in the study, tissue samples from their tumor may be taken before and during treatment to better understand how the medicine works.

During the study, people will take EP0031 regularly and visit the study site for check-ups. These visits will include physical examinations, blood tests, heart monitoring with an ECG, and scans to see how the cancer is responding to treatment. The study doctors will watch for any side effects and measure the amount of medicine in the blood to understand how the body processes it. Different groups of people will be placed into different cohorts based on their type of cancer, whether they have received previous RET-targeted treatment, and other factors. The study will continue until enough information is gathered about the safety and effectiveness of EP0031 in treating these types of cancer.

]]> Comparison of two doses of cabozantinib (60 mg vs 140 mg) in patients with progressive metastatic medullary thyroid cancer https://clinicaltrials.eu/trial/study-comparing-two-doses-of-cabozantinib-for-patients-with-progressive-metastatic-medullary-thyroid-cancer/ Wed, 29 Apr 2026 15:02:21 +0000 https://clinicaltrials.eu/trial/study-comparing-two-doses-of-cabozantinib-for-patients-with-progressive-metastatic-medullary-thyroid-cancer/ This study focuses on Metastatic Medullary Thyroid Cancer, which is a rare type of thyroid cancer that has spread to other parts of the body. The research evaluates two different doses of cabozantinib, a medication that comes in the form of tablets and capsules under the brand names CABOMETYX and COMETRIQ.

The purpose of the study is to compare the effectiveness and safety of two different daily doses of cabozantinib – 60 mg versus 140 mg – in patients whose cancer is getting worse. The medication is taken orally (by mouth) in the form of either film-coated tablets or hard capsules.

During the study, patients will be randomly assigned to receive one of the two doses of cabozantinib. Neither the patients nor their doctors will know which dose they are receiving. The study will track how well the treatment works by measuring if the cancer stops growing or shrinking, and how long patients live without their cancer getting worse.

]]> Study on the Effects of Selpercatinib in Patients Aged 12 and Older with Advanced Solid Tumors with RET Gene Alteration https://clinicaltrials.eu/trial/study-on-the-effects-of-selpercatinib-in-patients-aged-12-and-older-with-advanced-solid-tumors-with-ret-gene-alteration/ Wed, 29 Apr 2026 14:30:22 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-selpercatinib-in-patients-aged-12-and-older-with-advanced-solid-tumors-with-ret-gene-alteration/ This clinical trial is focused on studying the effects of a medication called selpercatinib, also known by its code name LOXO-292. The study is aimed at patients with advanced solid tumors, which are a type of cancer that forms in the tissues of the body. Specifically, the trial includes patients with tumors that have a change in a gene called RET. This includes certain types of thyroid cancer, such as medullary thyroid cancer, and other tumors where the RET gene is active.

The purpose of the study is to explore how well selpercatinib works in treating these cancers. The study is divided into two phases. In the first phase, the goal is to find the best dose of the medication that can be used safely. In the second phase, the study will look at how effective the medication is in shrinking the tumors. Patients will take the medication in the form of a capsule that is swallowed. Some patients in the study may receive a placebo, which is a substance with no active medication, to compare the effects.

Throughout the study, patients will have regular check-ups to monitor their health and the effects of the treatment. The study will continue until 2028, allowing researchers to gather enough information to understand the potential benefits and risks of using selpercatinib for treating these types of cancer. This research is important for developing new treatments for patients with advanced solid tumors that have limited options.

]]> Study Comparing Selpercatinib, Cabozantinib, and Vandetanib for Patients with Advanced RET-Mutant Medullary Thyroid Cancer https://clinicaltrials.eu/trial/study-comparing-selpercatinib-cabozantinib-and-vandetanib-for-patients-with-advanced-ret-mutant-medullary-thyroid-cancer/ Wed, 29 Apr 2026 14:29:22 +0000 https://clinicaltrials.eu/trial/study-comparing-selpercatinib-cabozantinib-and-vandetanib-for-patients-with-advanced-ret-mutant-medullary-thyroid-cancer/ This clinical trial is focused on studying a type of thyroid cancer known as RET-mutant medullary thyroid cancer. This is a specific form of thyroid cancer that is caused by changes in the RET gene. The study is comparing the effectiveness of a new treatment called Selpercatinib with two other existing treatments, Cabozantinib and Vandetanib. These treatments are known as kinase inhibitors, which are medications that can block certain proteins in cancer cells and may help to stop the cancer from growing.

The purpose of the study is to see how well Selpercatinib works compared to the other two treatments in patients who have not previously been treated with kinase inhibitors. Participants in the study will be randomly assigned to receive either Selpercatinib, Cabozantinib, or Vandetanib. The study will monitor the progress of the cancer and how it responds to the treatment over time. The treatments are taken orally, meaning they are swallowed in the form of a pill or capsule.

The study will take place over a period of time, and participants will have regular check-ups to monitor their health and the status of their cancer. The goal is to determine which treatment is most effective in slowing down or stopping the growth of the cancer. This information could help improve treatment options for people with RET-mutant medullary thyroid cancer in the future.

]]> Study on the Effects of Selpercatinib in Children with Advanced RET-Altered Solid Tumors or Primary Central Nervous System Tumors https://clinicaltrials.eu/trial/study-on-the-effects-of-selpercatinib-in-children-with-advanced-ret-altered-solid-tumors-or-primary-central-nervous-system-tumors/ Wed, 29 Apr 2026 14:28:18 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-selpercatinib-in-children-with-advanced-ret-altered-solid-tumors-or-primary-central-nervous-system-tumors/ This clinical trial is focused on studying the effects of a medication called Selpercatinib in children and young adults with advanced tumors. These tumors are either solid or located in the central nervous system, such as the brain or spinal cord, and have a specific change in their genes known as RET-altered. The purpose of the study is to understand how safe the medication is and how well it works in treating these types of tumors.

The study is divided into two phases. In the first phase, the main goal is to determine the safety of Selpercatinib and identify any side effects that might occur. In the second phase, the focus is on evaluating how well the tumors respond to the treatment. This involves measuring the size of the tumors to see if they shrink or disappear after taking the medication. The study will involve taking Selpercatinib in different forms, such as tablets or oral solutions, and it will be administered by mouth.

Participants in the study will be monitored closely to track their response to the treatment and any side effects they may experience. The study aims to provide valuable information on the potential benefits and risks of using Selpercatinib for treating these specific types of tumors in young patients. The trial is expected to continue until late 2024, with the hope of finding an effective treatment option for those affected by these challenging conditions.

]]> Study on Selpercatinib for Adults with Advanced or Metastatic Solid Tumors with RET Activation https://clinicaltrials.eu/trial/study-on-selpercatinib-for-adults-with-advanced-or-metastatic-solid-tumors-with-ret-activation/ Wed, 29 Apr 2026 14:27:14 +0000 https://clinicaltrials.eu/trial/study-on-selpercatinib-for-adults-with-advanced-or-metastatic-solid-tumors-with-ret-activation/ This clinical trial is focused on treating patients with certain types of advanced cancers, specifically those that have a change in a gene called Rearranged During Transfection (RET). The cancers being studied include Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Breast Cancer, Pancreatic Cancer, Papillary Thyroid Cancer, and other solid tumors with this specific gene change. The treatment being tested is a medication called selpercatinib, which is taken as a capsule by mouth.

The purpose of this study is to provide access to selpercatinib for patients who have these advanced cancers with the RET gene change. The study is designed to help patients who are not eligible for other ongoing clinical trials of selpercatinib. Participants will take the medication over a period of time, and their health will be monitored by their healthcare team. The study does not involve any specific data analysis or endpoints, meaning it is primarily focused on providing the treatment rather than collecting data for research purposes.

Patients who participate in this study will receive selpercatinib as part of an expanded access program, which is a way to provide treatment to patients who have no other options available. The treatment period can last up to 84 days, and the medication is taken orally. This study aims to support patients with advanced cancers by offering them a potential treatment option when other therapies are not suitable or available.

]]>